Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01343823 · ClinicalTrials.gov registry record · Phase 2
Evaluation of Ecallantide for Treatment of Angiotensin Converting Enzyme (ACE) Inhibitor Induced Angioedema
A Phase 2 study, sponsored by Shire.
- Terminated
- Registry status
- Phase 2
- Development phase
- 79
- Enrollment target
NCT01343823 is a Phase 2 study that was terminated before completion, run by Shire. The registered enrollment target is 79 participants.
The verdict
NCT01343823, a Phase 2 study, was terminated before completion, sponsored by Shire.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 79 participants
- Enrollment target
Study Summary
A double-blind, randomized, controlled trial comparing the safety and effectiveness of conventional therapy with ecallantide to conventional therapy with placebo.
Interventions
- DRUG placebo
- DRUG ecallantide 60 mg
- DRUG ecallantide 30 mg
- DRUG ecallantide 10 mg
- DRUG placebo match for 30 mg ecallantide arm
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 79 participants |
| Start Date | 2011-06-01 |
| Est. Completion | 2012-06-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01343823
The ClinicalTrials.gov registry entry for NCT01343823 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 79 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Shire, which has 245 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which placebo is the first listed.
NCT01343823 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01343823 about?
NCT01343823 is a clinical study titled "Evaluation of Ecallantide for Treatment of Angiotensin Converting Enzyme (ACE) Inhibitor Induced Angioedema". A double-blind, randomized, controlled trial comparing the safety and effectiveness of conventional therapy with ecallantide to conventional therapy with placebo.
What is the current status of trial NCT01343823?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 79 participants. The study started on 2011-06-01. Estimated completion is 2012-06-01.
What interventions are being tested in trial NCT01343823?
The interventions under investigation include: placebo (DRUG), ecallantide 60 mg (DRUG), ecallantide 30 mg (DRUG), ecallantide 10 mg (DRUG), placebo match for 30 mg ecallantide arm (DRUG).
Who is sponsoring clinical trial NCT01343823?
This trial is sponsored by Shire, which has 245 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.